What the Study Found (In Plain English)
Published in Gan to kagaku ryoho. Cancer & chemotherapy (2022), this phase iii randomized trial evaluating human clinical outcomes investigated: Advanced medical care is a system that allows the use of off-label treatments in conjunction with insurance reimbursement, and is used for clinical trials to evaluate off-label treatments. Key clinical takeaway: The JIPANG study failed to show the superiority of pemetrexed plus cisplatin in terms of recurrence-free survival, as primary endpoint.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Gan to kagaku ryoho. Cancer & chemotherapy, 2022-12-15; Phase III Randomized Trial; Rigor 82/100): The JIPANG study failed to show the superiority of pemetrexed plus cisplatin in terms of recurrence-free survival, as primary endpoint.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.